Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/35177
Tipo
ArtículoDerechos de autor
Acceso abierto
Fecha del embargo
2020-08-29
Colecciones
- INI - Artigos de Periódicos [3398]
Metadatos
Mostrar el registro completo del ítem
PHARMACOKINETICS OF RIFAMPIN AND ISONIAZID IN TUBERCULOSIS-HIVCOINFECTED PATIENTS RECEIVING NEVIRAPINE-OR EFAVIRENZ-BASED ANTIRETROVIRAL TREATMENT
Antiretroviral treatment
Rifampin
Isoniazid
Nevirapine
Efavirenz
Autor
Afiliación
Ministério da Saúde. Instituto Nacional de Saúde. Maputo, Mozambique / Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France.
Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France.
Epicentre. Paris, France.
Ministério da Saúde. Instituto Nacional de Saúde. Maputo, Mozambique.
Epicentre. Paris, France.
Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France / University Paris Sud. Faculty of Pharmacy. Paris, France.
Epicentre. Paris, France.
Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France.
Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France.
Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France.
Epicentre. Paris, France.
Ministério da Saúde. Instituto Nacional de Saúde. Maputo, Mozambique.
Epicentre. Paris, France.
Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France / University Paris Sud. Faculty of Pharmacy. Paris, France.
Epicentre. Paris, France.
Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France.
Resumen en ingles
This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique. Thirty-eight patients on antituberculosis therapy based on rifampin and isoniazid participated in the substudy (57.9% males; median age, 33 years; median weight, 51.9
kg; median CD4 T cell count, 104 cells/l; median HIV-1 RNA load, 5.5 log copies/ml). The daily doses of rifampin and isoniazid were 10 and 5 mg/kg of body weight, respectively. Twenty-one patients received 200 mg of nevirapine twice a day (b.i.d.), and 17 patients received 600 mg of efavirenz once a day (q.d.) in combination with lamivudine and stavudine from day 1 until the end of the study. Blood samples were collected at regular time-dosing intervals after morning administration of a fixed-dose combination of rifampin and isoniazid. When rifampin was administered alone, the median maximum concentration of drug in serum (Cmax) and the area under the concentration-time curve (AUC) at steady state were 6.59 mg/liter (range, 2.70 to 14.07 mg/
liter) and 27.69 mg · h/liter (range, 11.41 to 109.75 mg · h/liter), respectively. Concentrations remained unchanged when rifampin was coadministered with nevirapine or efavirenz. When isoniazid was administered alone, the median isoniazid Cmax and AUC at steady state were 5.08 mg/liter (range, 1.26 to 11.51 mg/liter) and 20.92 mg · h/liter (range, 7.73 to 56.95 mg · h/liter), respectively. Concentrations remained unchanged when isoniazid was coadministered with nevirapine; however, a 29% decrease in the isoniazid AUC was observed when isoniazid was combined with efavirenz. The pharmacokinetic parameters of rifampin and isoniazid when coadministered with nevirapine or efavirenz were not altered to a clinically significant extent in these severely immunosuppressed HIV-infected patients. Patients experienced favorable clinical outcomes.
Palabras clave en ingles
HIV-tuberculosis coinfectionAntiretroviral treatment
Rifampin
Isoniazid
Nevirapine
Efavirenz
Compartir